<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Family Medicine Update &#187; attention</title>
	<atom:link href="http://www.familymedicineupdate.com/tag/attention/feed" rel="self" type="application/rss+xml" />
	<link>http://www.familymedicineupdate.com</link>
	<description>Important Medical news for family physicians and primary care providers</description>
	<lastBuildDate>Mon, 06 Sep 2010 05:10:13 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.0.1</generator>
		<item>
		<title>Impact of an informed choice invitation on uptake of screening for diabetes in primary care (DICISION): randomised trial.</title>
		<link>http://www.familymedicineupdate.com/impact-of-an-informed-choice-invitation-on-uptake-of-screening-for-diabetes-in-primary-care-dicision-randomised-trial</link>
		<comments>http://www.familymedicineupdate.com/impact-of-an-informed-choice-invitation-on-uptake-of-screening-for-diabetes-in-primary-care-dicision-randomised-trial#comments</comments>
		<pubDate>Fri, 21 May 2010 14:45:30 +0000</pubDate>
		<dc:creator>khalid Al Saffar</dc:creator>
				<category><![CDATA[Diabetes]]></category>
		<category><![CDATA[Research]]></category>
		<category><![CDATA[attention]]></category>
		<category><![CDATA[bmj]]></category>
		<category><![CDATA[identified-from]]></category>

		<guid isPermaLink="false">http://www.familymedicineupdate.com/impact-of-an-informed-choice-invitation-on-uptake-of-screening-for-diabetes-in-primary-care-dicision-randomised-trial</guid>
		<description><![CDATA[ Related Articles Impact of an informed choice invitation on uptake of screening for diabetes in primary care (DICISION): randomised trial. BMJ. 2010;340:c2138 Authors: Marteau TM, Mann E, Prevost AT, Vasconcelos JC, Kellar I, Sanderson S, Parker M, Griffin S, Sutton S, Kinmonth AL OBJECTIVE: To compare the effect of an invitation promoting informed choice for screening with a standard invitation on attendance and motivation to engage in preventive action. ]]></description>
		<wfw:commentRss>http://www.familymedicineupdate.com/impact-of-an-informed-choice-invitation-on-uptake-of-screening-for-diabetes-in-primary-care-dicision-randomised-trial/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Acute myelogenous leukemia and myelodysplasia secondary to breast cancer treatment: case studies and literature review.</title>
		<link>http://www.familymedicineupdate.com/acute-myelogenous-leukemia-and-myelodysplasia-secondary-to-breast-cancer-treatment-case-studies-and-literature-review</link>
		<comments>http://www.familymedicineupdate.com/acute-myelogenous-leukemia-and-myelodysplasia-secondary-to-breast-cancer-treatment-case-studies-and-literature-review#comments</comments>
		<pubDate>Fri, 05 Feb 2010 22:10:54 +0000</pubDate>
		<dc:creator>Smith</dc:creator>
				<category><![CDATA[Research]]></category>
		<category><![CDATA[am j med sci]]></category>
		<category><![CDATA[attention]]></category>
		<category><![CDATA[chemotherapy]]></category>
		<category><![CDATA[development]]></category>
		<category><![CDATA[the-development]]></category>

		<guid isPermaLink="false">http://www.familymedicineupdate.com/acute-myelogenous-leukemia-and-myelodysplasia-secondary-to-breast-cancer-treatment-case-studies-and-literature-review</guid>
		<description><![CDATA[ Related Articles Acute myelogenous leukemia and myelodysplasia secondary to breast cancer treatment: case studies and literature review. Am J Med Sci. 2010 Jan;339(1):36-40 Authors: Cole M, Strair R BACKGROUND AND PURPOSE: Chemotherapy and radiation therapy for breast cancer are known to increase the risk of developing a myelodysplastic syndrome (MDS) and/or acute myelogenous leukemia (AML). Alkylating agents and topoisomerase II inhibitors, fundamental to the treatment of breast cancer, are the most likely contributors to this increase in risk]]></description>
		<wfw:commentRss>http://www.familymedicineupdate.com/acute-myelogenous-leukemia-and-myelodysplasia-secondary-to-breast-cancer-treatment-case-studies-and-literature-review/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

<!-- Performance optimized by W3 Total Cache. Learn more: http://www.w3-edge.com/wordpress-plugins/


Served from: www.familymedicineupdate.com @ 2010-09-07 05:47:07 -->